KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy.

Esther Reijnders, Patrick M Bossuyt, J Wouter Jukema, L Renee Ruhaak, Fred P H T M Romijn, Michael Szarek, Stella Trompet, Deepak L Bhatt, Vera A Bittner, Rafael Diaz, Sergio Fazio, Irena Stevanovic, Shaun G Goodman, Robert A Harrington, Harvey D White, Philippe Gabriel Steg, Gregory G Schwartz, Christa M Cobbaert

Arterioscler Thromb Vasc Biol 45(11) 2111-2123

PMID40995631
PMCIDPMC12543001
DOI10.1161/ATVBAHA.124.322336
发表日期2025-09-25
入排依据:未发现恶性肿瘤人群证据。
已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:ROC 图;Figure 2:森林图/亚组分析图;Figure 3:研究设计图。
摘要

摘要

BACKGROUND: Residual cardiovascular risk remains, despite achieving low-density lipoprotein cholesterol targets with high-intensity statins. Traditional risk scores are suboptimal. This study evaluated the prognostic utility of a 9-plex apolipoprotein panel in recent patients with acute coronary syndrome on statins and its role in predicting treatment benefit by alirocumab, a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor, enabling precision medicine. METHODS: Baseline serum samples from 11 843 participants in the ODYSSEY OUTCOMES trial (https://www.clinicaltrials.gov; Unique identifier: NCT01663402) were analyzed using mass spectrometry to measure Apo(a), ApoA-I, ApoA-II, ApoA-IV, ApoB, ApoC-I, ApoC-II, ApoC-III, and ApoE. Using logistic regression, probabilities of major adverse cardiovascular events (MACE) and all-cause death over a median follow-up of 2.9 years were estimated based on baseline apolipoproteins and lipid concentrations. Clinical performance was assessed by comparing the area under the curve (AUC) of 3 models: the apolipoprotein panel, the lipid panel (total cholesterol, high-density lipoprotein cholesterol, and triglycerides), and a combination. In addition, prediction models estimating the treatment benefit of alirocumab by the apolipoprotein panel were developed. RESULTS: The prognostic performance of the apolipoprotein panel for MACE showed an AUC (95% CI) of 0.648 (0.626-0.670), compared with 0.579 (0.557-0.602) for the lipid panel. For all-cause death, the apolipoprotein panel had an AUC of 0.699 (0.664-0.733), while the lipid panel had an AUC of 0.599 (0.564-0.635). Adding the apolipoprotein panel significantly improved the performance of the conventional lipid panel (P<0.0001): AUC, 0.659 (0.637-0.681) for MACE and 0.724 (0.691-0.756) for all-cause death. Higher risk for MACE based on the baseline apolipoprotein panel was found to predict greater treatment benefit with alirocumab. CONCLUSIONS: A multiplex apolipoprotein panel led to better prediction of MACE and all-cause death, beyond lipids, in patients with postacute coronary syndrome on optimized statin therapy. The panel also predicts the treatment benefit of alirocumab. Further validation of this approach is now needed, and if confirmed and improved, it could lead to better disease prediction and management in the future.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Clinical performance of prediction models on major adverse cardiovascular event (MACE) and all-cause death. Receiver operating characteristic (ROC) curves of clinical performance for MACE ( top ) and all-cause death ( bottom ) based on the prognostic models based on the apolipoprotein panel ( left ) consisting of baseline apolipoproteins and ApoE phenotype, the lipid panel ( center ) consisting of baseline total cholesterol, high-density lipoprotein cholesterol, and triglycerides, and the combination of the 2 panels ( right ).
非 KM Figure
Figure 2Figure 2. Model-based calculated risk fraction in the placebo and targeted treatment group of the apolipoprotein panel for major adverse cardiovascular event (MACE) and all-cause death. Scatter plots of model-based calculated risk if allocated to placebo or alirocumab for MACE ( A ) and all-cause death ( C ). B and D , Stacked distribution of risk in the subgroups defined to achieve meaningful benefit or not for MACE and all-cause death (absolute risk reduction with alirocumab of ≥2.1% for MACE and ≥0.7% for all-cause death). Risk is calculated based on the apolipoprotein panel.
非 KM Figure
Figure 3Figure 3. Probability thresholds for treatment allocation based on estimated treatment benefit by the apolipoprotein panel. A and B , Clinical decision limit at 8% and 17% estimated risk of major adverse cardiovascular event (MACE) and the resulting sensitivity and specificity, respectively. C , The sensitivity or specificity at specific probability thresholds. D , Table with 5 examples of probability thresholds and the resulting sensitivity and specificity.
非 KM Figure